Viewing Study NCT01290718


Ignite Creation Date: 2025-12-25 @ 4:58 AM
Ignite Modification Date: 2025-12-26 @ 3:58 AM
Study NCT ID: NCT01290718
Status: TERMINATED
Last Update Posted: 2014-12-17
First Post: 2011-02-03
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Sponsor: Hoffmann-La Roche
Organization: